GLPwatch
Papers (10404)
Page 90 of 174, ranked by citation count.
- Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
- Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
- Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease.
- Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.
- Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial.
- Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
- Type 2 diabetes in children and adolescents: distinct characteristics and evidence-based management.
- Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
- Vertical sleeve gastrectomy and semaglutide have distinct effects on skeletal health and heart function in obese male mice.
- The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
- GLP-1 Agonists in Aesthetic Surgery: Implications for Perioperative Outcomes and Body Contouring Procedures.
- Anti-obesogenic and hypolipidemic effects of a glucagon-like peptide-1 receptor agonist derived from the saliva of the Gila monster.
- Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
- Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article.
- Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes.
- Determining the Effects of Combined Liraglutide and Phentermine on Metabolic Parameters, Blood Pressure, and Heart Rate in Lean and Obese Male Mice.
- Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration.
- Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study.
- Determination of the Plasma Protein Binding of Liraglutide Using the EScalate<sup>*</sup> Equilibrium Shift Assay.
- Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
- Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program.
- [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
- The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
- Evaluating appetite/satiety hormones and eating behaviours as predictors of weight loss maintenance with GLP-1RA therapy in adolescents with severe obesity.
- Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.
- Glycogen synthesis kinase-3β involves in the analgesic effect of liraglutide on diabetic neuropathic pain.
- Combination therapy with semaglutide and rosiglitazone as a synergistic treatment for diabetic retinopathy in rodent animals.
- Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programme.
- Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
- Cardiovascular Outcome Trials with Glucose-Lowering Drugs.
- Characterization and Role of Glucagon-Like Peptide 1 Receptor in the Lacrimal Gland: Novel Insights into Diabetic Dry Eye Pathogenesis.
- Does semaglutide reduce alcohol intake in Danish patients with alcohol use disorder and comorbid obesity? Trial protocol of a randomised, double-blinded, placebo-controlled clinical trial (the SEMALCO trial).
- Increased vision impairment reports linked to semaglutide: analysis of FDA adverse event data.
- A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
- A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxia-Reoxygenation Injury in Cultured Cardiomyocytes.
- Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment.
- GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis.
- Liraglutide effects on epicardial adipose tissue micro-RNAs and intra-operative glucose control.
- SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.
- Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?
- Exendin-4 decreases ghrelin levels through mTOR signaling.
- Tirzepatide's innovative applications in the management of type 2 diabetes and its future prospects in cardiovascular health.
- Successful Implementation of a Multidisciplinary Weight Loss Program Including GLP1 Receptor Agonists for Liver Transplant Candidates With High Body Mass Index.
- Metabolic improvement with short-term, glucagon-like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
- Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats.
- Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials.
- What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
- Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
- Systemic and gut microbiome changes with metformin and liraglutide in youth-onset type 2 diabetes: the MIGHTY study.
- Oxidation of methionine - is it limiting the diagnostic properties of 99mTc-labeled Exendin-4, a Glucagon-Like Peptide-1 receptor agonist?
- Obesity-Related Glomerulosclerosis-How Adiposity Damages the Kidneys.
- Notch signaling is involved in the antiapoptotic effects of liraglutide on rat H9c2 cardiomyocytes exposed to hypoxia followed by reoxygenation.
- A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide.
- Emerging Therapies for Nonalcoholic Fatty Liver Disease.
- Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
- Titration and discontinuation of semaglutide for weight management in commercially insured US adults.
- Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.